Estimating the mortality rate of hepatitis C using multiple data sources

Epidemiology and Infection

Volumn 133, Issue 1, 2005, Pages 121-125

  Wu, C ^a   Chang, H G ^a,b   McNutt, L A ^a   Smith, P F ^a,b  

^a UNIVERSITY AT ALBANY   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; HEPATITIS C; HOSPITAL DISCHARGE; HOSPITAL INFORMATION SYSTEM; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; DATABASES, FACTUAL; EPIDEMIOLOGIC METHODS; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NEW YORK; PATIENT DISCHARGE; RISK FACTORS;

EID: 14044272650     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268804003103     Document Type: Article

References (16)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
2. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-1905.
3. Liang TJ, Jeffers L, Reddy RK, et al. Fulminant or subfulminant non-A, non-B viral hepatitis: the role of hepatitis C and E viruses. Gastroenterology 1993; 104: 556-562.
4. Nowicki MJ, Balistreri WF. The hepatitis C virus: identification, epidemiology, and clinical controversies. J Pediatr Gastroenterol Nutr 1995; 20: 248-274.
5. Degos F. Natural history of hepatitis C virus infection. Nephrol Dial Transplant 1996; 11 (Suppl): 16-18.
6. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906-1911.
7. Di Bisceglie AM, Order SE, Klein JL, et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991; 86: 335-338.
8. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C (HCV) and HCV-related chronic diseases. MMWR 1998; 47: 1-38.
9. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-1569.
10. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
11. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
12. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
13. International classification of diseases, 9th revision, clinical modification, 4th edn. Los Angeles, CA: Practice Management Information Corporation, 1995.
14. New York State Department of Health. Vital Statistics of New York State, 1997 (http://www.health.state.ny.us/nysdoh/vital_statistics/1997/toc.htm). Accessed September 2002.
15. Chandra Sekar C, Deming WE. On a method of estimating birth and death rates and the extent of registration. J Am Stat Assoc 1949; 44: 101-115.
16. Hook EB, Regal RR. Capture-recapture methods in epidemiology. Epidemiol Rev 1995; 17: 243-264.